Content and face validity and feasibility of 5 candidate instruments for psoriatic arthritis randomized controlled trials: The PsA OMERACT core set workshop at the GRAPPA 2017 annual meeting

Richard Holland; William Tillett; Alexis Ogdie; Ying Y. Leung; Dafna D. Gladman; Kristina Callis Duffin; Laura C. Coates; Philip J. Mease; Lihi Eder; Vibeke Strand; Musaab Elmamoun; Pil Højgaard; Jeffrey Chau; Maarten De Wit; Niti Goel; Chris A. Lindsay; Oliver FitzGerald; Bev Shea; Dorcas Beaton; Ana Maria Orbai

doi:10.3899/JRHEUM.180142

Content and face validity and feasibility of 5 candidate instruments for psoriatic arthritis randomized controlled trials: The PsA OMERACT core set workshop at the GRAPPA 2017 annual meeting

Richard Holland, William Tillett, Alexis Ogdie, Ying Y. Leung, Dafna D. Gladman, Kristina Callis Duffin, Laura C. Coates, Philip J. Mease, Lihi Eder, Vibeke Strand, Musaab Elmamoun, Pil Højgaard, Jeffrey Chau, Maarten De Wit, Niti Goel, Chris A. Lindsay, Oliver FitzGerald, Bev Shea, Dorcas Beaton, Ana Maria Orbai

School of Medicine

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Core Set working group is in the process of selecting core instruments for PsA clinical trials. During a 2-h workshop and breakout group discussions at the GRAPPA 2017 annual meeting in Amsterdam, the Netherlands, participants discussed the first set of candidate instruments to be taken through the OMERACT Filter 2.1 instrument selection process: 66/68 swollen/tender joint count (66/68JC), Spondyloarthritis Consortium of Canada (SPARCC) enthesitis index, patient's global assessment (GRAPPA and OMERACT formulations), Health Assessment Questionnaire-Disability Index (HAQ-DI), Psoriatic Arthritis Impact of Disease (PsAID) questionnaires 9 and 12, and Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue. Based on the assessment of domain match (content and face validity) and feasibility according to the OMERACT instrument selection criteria, the working group recommends continuing with appraisal of construct validity and discrimination for 66/68JC, SPARCC, PsAID 9 and 12, HAQ-DI, and FACIT-Fatigue. In addition, it recommends repeating the OMERACT Filter 2.1 process for patient global instruments because of insufficient votes. Additional sets of candidate instruments for the PsA core instrument set will be evaluated in a similar process.

Original language	English (US)
Pages (from-to)	17-25
Number of pages	9
Journal	Journal of Rheumatology
Volume	94
DOIs	https://doi.org/10.3899/JRHEUM.180142
State	Published - Jun 1 2018

Keywords

Core Set
GRAPPA
Outcome Measures in Rheumatology
Psoriasis
Psoriatic Arthritis

ASJC Scopus subject areas

Rheumatology
Immunology and Allergy
Immunology

Access to Document

10.3899/JRHEUM.180142

Cite this

Holland, R., Tillett, W., Ogdie, A., Leung, Y. Y., Gladman, D. D., Duffin, K. C., Coates, L. C., Mease, P. J., Eder, L., Strand, V., Elmamoun, M., Højgaard, P., Chau, J., De Wit, M., Goel, N., Lindsay, C. A., FitzGerald, O., Shea, B., Beaton, D., & Orbai, A. M. (2018). Content and face validity and feasibility of 5 candidate instruments for psoriatic arthritis randomized controlled trials: The PsA OMERACT core set workshop at the GRAPPA 2017 annual meeting. Journal of Rheumatology, 94, 17-25. https://doi.org/10.3899/JRHEUM.180142

Content and face validity and feasibility of 5 candidate instruments for psoriatic arthritis randomized controlled trials: The PsA OMERACT core set workshop at the GRAPPA 2017 annual meeting. / Holland, Richard; Tillett, William; Ogdie, Alexis et al.
In: Journal of Rheumatology, Vol. 94, 01.06.2018, p. 17-25.

Research output: Contribution to journal › Article › peer-review

Holland, R, Tillett, W, Ogdie, A, Leung, YY, Gladman, DD, Duffin, KC, Coates, LC, Mease, PJ, Eder, L, Strand, V, Elmamoun, M, Højgaard, P, Chau, J, De Wit, M, Goel, N, Lindsay, CA, FitzGerald, O, Shea, B, Beaton, D & Orbai, AM 2018, 'Content and face validity and feasibility of 5 candidate instruments for psoriatic arthritis randomized controlled trials: The PsA OMERACT core set workshop at the GRAPPA 2017 annual meeting', Journal of Rheumatology, vol. 94, pp. 17-25. https://doi.org/10.3899/JRHEUM.180142

@article{d249818f7f8e4e228b1c8485ec259c3b,

title = "Content and face validity and feasibility of 5 candidate instruments for psoriatic arthritis randomized controlled trials: The PsA OMERACT core set workshop at the GRAPPA 2017 annual meeting",

abstract = "The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Core Set working group is in the process of selecting core instruments for PsA clinical trials. During a 2-h workshop and breakout group discussions at the GRAPPA 2017 annual meeting in Amsterdam, the Netherlands, participants discussed the first set of candidate instruments to be taken through the OMERACT Filter 2.1 instrument selection process: 66/68 swollen/tender joint count (66/68JC), Spondyloarthritis Consortium of Canada (SPARCC) enthesitis index, patient's global assessment (GRAPPA and OMERACT formulations), Health Assessment Questionnaire-Disability Index (HAQ-DI), Psoriatic Arthritis Impact of Disease (PsAID) questionnaires 9 and 12, and Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue. Based on the assessment of domain match (content and face validity) and feasibility according to the OMERACT instrument selection criteria, the working group recommends continuing with appraisal of construct validity and discrimination for 66/68JC, SPARCC, PsAID 9 and 12, HAQ-DI, and FACIT-Fatigue. In addition, it recommends repeating the OMERACT Filter 2.1 process for patient global instruments because of insufficient votes. Additional sets of candidate instruments for the PsA core instrument set will be evaluated in a similar process.",

keywords = "Core Set, GRAPPA, Outcome Measures in Rheumatology, Psoriasis, Psoriatic Arthritis",

author = "Richard Holland and William Tillett and Alexis Ogdie and Leung, {Ying Y.} and Gladman, {Dafna D.} and Duffin, {Kristina Callis} and Coates, {Laura C.} and Mease, {Philip J.} and Lihi Eder and Vibeke Strand and Musaab Elmamoun and Pil H{\o}jgaard and Jeffrey Chau and {De Wit}, Maarten and Niti Goel and Lindsay, {Chris A.} and Oliver FitzGerald and Bev Shea and Dorcas Beaton and Orbai, {Ana Maria}",

note = "Funding Information: The authors acknowledge Ina Campbell for her participation in the workshop at the GRAPPA meeting as a patient research partner. We thank Michelle Jones from the Johns Hopkins Arthritis Center for preparing the breakout group materials and programming the steering group survey. We thank Pam Love and Sharon Andrews for their help in coordinating working group teleconferences and communications, and we thank Tori Fischer for editorial assistance. Funding Information: The PsA Core Set patient research partner pre-meeting was supported by a research grant from Novartis to GRAPPA. AMO is funded in part by grants from the US National Institutes of Health (P30 AR070254-01), the Rheumatology Research Foundation (RRF Scientist Development Award), and the Staurulakis Discovery Award. Publisher Copyright: {\textcopyright} 2018 Journal of Rheumatology. All rights reserved.",

year = "2018",

month = jun,

day = "1",

doi = "10.3899/JRHEUM.180142",

language = "English (US)",

volume = "94",

pages = "17--25",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

}

TY - JOUR

T1 - Content and face validity and feasibility of 5 candidate instruments for psoriatic arthritis randomized controlled trials

T2 - The PsA OMERACT core set workshop at the GRAPPA 2017 annual meeting

AU - Holland, Richard

AU - Tillett, William

AU - Ogdie, Alexis

AU - Leung, Ying Y.

AU - Gladman, Dafna D.

AU - Duffin, Kristina Callis

AU - Coates, Laura C.

AU - Mease, Philip J.

AU - Eder, Lihi

AU - Strand, Vibeke

AU - Elmamoun, Musaab

AU - Højgaard, Pil

AU - Chau, Jeffrey

AU - De Wit, Maarten

AU - Goel, Niti

AU - Lindsay, Chris A.

AU - FitzGerald, Oliver

AU - Shea, Bev

AU - Beaton, Dorcas

AU - Orbai, Ana Maria

N1 - Funding Information: The authors acknowledge Ina Campbell for her participation in the workshop at the GRAPPA meeting as a patient research partner. We thank Michelle Jones from the Johns Hopkins Arthritis Center for preparing the breakout group materials and programming the steering group survey. We thank Pam Love and Sharon Andrews for their help in coordinating working group teleconferences and communications, and we thank Tori Fischer for editorial assistance. Funding Information: The PsA Core Set patient research partner pre-meeting was supported by a research grant from Novartis to GRAPPA. AMO is funded in part by grants from the US National Institutes of Health (P30 AR070254-01), the Rheumatology Research Foundation (RRF Scientist Development Award), and the Staurulakis Discovery Award. Publisher Copyright: © 2018 Journal of Rheumatology. All rights reserved.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Core Set working group is in the process of selecting core instruments for PsA clinical trials. During a 2-h workshop and breakout group discussions at the GRAPPA 2017 annual meeting in Amsterdam, the Netherlands, participants discussed the first set of candidate instruments to be taken through the OMERACT Filter 2.1 instrument selection process: 66/68 swollen/tender joint count (66/68JC), Spondyloarthritis Consortium of Canada (SPARCC) enthesitis index, patient's global assessment (GRAPPA and OMERACT formulations), Health Assessment Questionnaire-Disability Index (HAQ-DI), Psoriatic Arthritis Impact of Disease (PsAID) questionnaires 9 and 12, and Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue. Based on the assessment of domain match (content and face validity) and feasibility according to the OMERACT instrument selection criteria, the working group recommends continuing with appraisal of construct validity and discrimination for 66/68JC, SPARCC, PsAID 9 and 12, HAQ-DI, and FACIT-Fatigue. In addition, it recommends repeating the OMERACT Filter 2.1 process for patient global instruments because of insufficient votes. Additional sets of candidate instruments for the PsA core instrument set will be evaluated in a similar process.

AB - The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Core Set working group is in the process of selecting core instruments for PsA clinical trials. During a 2-h workshop and breakout group discussions at the GRAPPA 2017 annual meeting in Amsterdam, the Netherlands, participants discussed the first set of candidate instruments to be taken through the OMERACT Filter 2.1 instrument selection process: 66/68 swollen/tender joint count (66/68JC), Spondyloarthritis Consortium of Canada (SPARCC) enthesitis index, patient's global assessment (GRAPPA and OMERACT formulations), Health Assessment Questionnaire-Disability Index (HAQ-DI), Psoriatic Arthritis Impact of Disease (PsAID) questionnaires 9 and 12, and Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue. Based on the assessment of domain match (content and face validity) and feasibility according to the OMERACT instrument selection criteria, the working group recommends continuing with appraisal of construct validity and discrimination for 66/68JC, SPARCC, PsAID 9 and 12, HAQ-DI, and FACIT-Fatigue. In addition, it recommends repeating the OMERACT Filter 2.1 process for patient global instruments because of insufficient votes. Additional sets of candidate instruments for the PsA core instrument set will be evaluated in a similar process.

KW - Core Set

KW - GRAPPA

KW - Outcome Measures in Rheumatology

KW - Psoriasis

KW - Psoriatic Arthritis

UR - http://www.scopus.com/inward/record.url?scp=85054391204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054391204&partnerID=8YFLogxK

U2 - 10.3899/JRHEUM.180142

DO - 10.3899/JRHEUM.180142

M3 - Article

C2 - 29858348

AN - SCOPUS:85054391204

SN - 0315-162X

VL - 94

SP - 17

EP - 25

JO - Journal of Rheumatology

JF - Journal of Rheumatology

ER -

Content and face validity and feasibility of 5 candidate instruments for psoriatic arthritis randomized controlled trials: The PsA OMERACT core set workshop at the GRAPPA 2017 annual meeting

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this